01:56 AM EST, 11/02/2026 (MT Newswires) -- Fresenius SE (FRE.F) signed a development agreement with WuXi Biologics to gain exclusive option rights for up to 37 potential biosimilar candidates, according to a Monday release. The partnership could expand the German healthcare company's biosimilars pipeline to up to 66 in the next decade from the existing 29 marketed molecules. The company will have the flexibility to select which biosimilar candidates to develop based on market potential, development risk, and expected returns. Fresenius will retain exclusive global sales rights and full commercial earnings from products developed under the agreement. It will pay WuXi Biologics for development services for each selected biosimilar candidate.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.